[go: up one dir, main page]

AU4414099A - Protein oligomer compositions comprising endostatin protein and methods of usingthe same - Google Patents

Protein oligomer compositions comprising endostatin protein and methods of usingthe same

Info

Publication number
AU4414099A
AU4414099A AU44140/99A AU4414099A AU4414099A AU 4414099 A AU4414099 A AU 4414099A AU 44140/99 A AU44140/99 A AU 44140/99A AU 4414099 A AU4414099 A AU 4414099A AU 4414099 A AU4414099 A AU 4414099A
Authority
AU
Australia
Prior art keywords
protein
methods
endostatin
oligomer compositions
usingthe same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU44140/99A
Inventor
M. Judah Folkman
Kashi Javaherian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU4414099A publication Critical patent/AU4414099A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU44140/99A 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of usingthe same Abandoned AU4414099A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US8789098P 1998-06-03 1998-06-03
US60087890 1998-06-03
US9239398P 1998-07-10 1998-07-10
US60092393 1998-07-10
US9879098P 1998-09-01 1998-09-01
US607098790 1998-09-01
PCT/US1999/012278 WO1999062944A2 (en) 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of using the same

Publications (1)

Publication Number Publication Date
AU4414099A true AU4414099A (en) 1999-12-20

Family

ID=27375776

Family Applications (1)

Application Number Title Priority Date Filing Date
AU44140/99A Abandoned AU4414099A (en) 1998-06-03 1999-06-03 Protein oligomer compositions comprising endostatin protein and methods of usingthe same

Country Status (5)

Country Link
JP (1) JP2002517186A (en)
KR (1) KR20010052566A (en)
AU (1) AU4414099A (en)
CA (1) CA2331370A1 (en)
WO (1) WO1999062944A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440729B1 (en) 1995-06-30 2002-08-27 University Of Kansas Medical Center Treating angiogenesis-mediated diseases with the α2 monomer of type IV collagen
US6358735B1 (en) 1995-06-30 2002-03-19 University Of Kansas Medical Center Method for inhibiting angiogenesis and tumors with the isolated NC1 α3 chain monomer of type IV collagen
DK1037927T3 (en) 1997-12-08 2004-09-06 Emd Lexigen Res Ct Corp Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
CA2339331C (en) * 1998-08-25 2011-03-01 Lexigen Pharmaceuticals Corporation Expression and export of angiogenesis inhibitors as immunofusins
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
RU2263118C2 (en) 1999-08-09 2005-10-27 Лексиген Фармасьютикэлс Корп. Complexes of antibodies with some cytokines
JP2003514552A (en) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング Erythropoietin morphology with improved properties
CA2399832C (en) 2000-02-11 2011-09-20 Stephen D. Gillies Enhancing the circulating half-life of antibody-based fusion proteins
CA2412845C (en) 2000-06-29 2014-07-22 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
PL206701B1 (en) 2001-03-07 2010-09-30 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
WO2002090566A2 (en) 2001-05-03 2002-11-14 Merck Patent Gmbh Recombinant tumor specific antibody and use thereof
CA2469151C (en) 2001-12-04 2013-08-13 Merck Patent Gesellschaft Mit Beschraenkter Haftung Immunocytokines with modulated selectivity
PT1572748E (en) 2002-12-17 2010-09-28 Merck Patent Gmbh Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
US7524811B2 (en) 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
EP1668129B1 (en) * 2003-08-29 2008-10-29 Children's Medical Center Corporation Anti-angiogenic peptides from the n-terminus of endostatin
FR2898895B1 (en) * 2006-03-23 2012-04-06 Univ Reims Champagne Ardenne CYCLOPEPTIDE WITH ANTI-CANCER ACTIVITY DERIVED FROM TYPE IV COLLAGEN
BRPI0605212B8 (en) * 2006-12-12 2021-05-25 Univ Rio De Janeiro production process of dimerized or oligomerized endostatin, dimerized or oligomerized endostatin and pharmaceutical composition
WO2009145489A2 (en) * 2008-04-04 2009-12-03 주식회사 프로셀제약 Cell-permeable endostatin recombinant protein, a polynucleotide coated with the same, and an anti-cancer preparation containing the same as an active component
EP2561888A1 (en) * 2011-08-23 2013-02-27 Deutsches Krebsforschungszentrum Protein comprising NC-1 for treating angiogenesis-related diseases
KR102282691B1 (en) * 2013-09-30 2021-07-27 추가이 세이야쿠 가부시키가이샤 Method for producing antigen-binding molecule using modified helper phage
KR20180033499A (en) * 2015-06-05 2018-04-03 아이바이오, 인크. Endostatin fragments and variants for use in treating fibrosis
US11845784B2 (en) 2018-04-17 2023-12-19 Heidelberg Biotech Gmbh Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising NC-1-Fc

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1202932A (en) * 1995-10-23 1998-12-23 儿童医学中心公司 Therapeutic antiangiogenic compositions and methods

Also Published As

Publication number Publication date
CA2331370A1 (en) 1999-12-09
WO1999062944A2 (en) 1999-12-09
JP2002517186A (en) 2002-06-18
KR20010052566A (en) 2001-06-25
WO1999062944A3 (en) 2000-04-06

Similar Documents

Publication Publication Date Title
AU4414099A (en) Protein oligomer compositions comprising endostatin protein and methods of usingthe same
AU4008495A (en) Tcl-1 gene and protein and related methods and compositions
AU2805897A (en) Inhibitors of protein farnesyltransferase
AU1833797A (en) Multistrand twist cereal pieces and method of preparation
AU5081298A (en) Surgical method and composition therefor
AU3767097A (en) Shampoo compositions and method
AUPN766296A0 (en) Trocar and introducing kit
AU3066699A (en) Smallpox inhibitor of complement enzymes (spice) protein and methods of inhibiting complement activation
AU3641597A (en) Methods and compositions comprising r-ibuprofen
AU3648697A (en) Thermostable mutl genes and proteins and uses therefor
AUPQ196799A0 (en) Method of preservation of amnion and uses thereof
AU4100199A (en) Compositions and methods for enhancing protein anabolism and detoxification
AU2670897A (en) Fibulin pharmaceutical compositions and related methods
AU4006695A (en) Calcineurin interacting protein compositions and methods
AU1919699A (en) Micro-catheters and methods of their manufacture
AU7134598A (en) Plant propagation compositions and methods
AU3451397A (en) Modified protein g and fragments thereof
EP1374894A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU2710400A (en) Monocyte-derived nucleic acids and related compositions and methods
AU4686299A (en) Nek-related and bub1-related protein kinases
AU1849297A (en) Compositions and methods for enzyme deactivation
AU1856297A (en) Lyst1 and lyst2 gene compositions and methods of use
AU3988299A (en) Geminin genes and proteins
AU4207899A (en) Lentiviral vector compositions and methods of use
AU4839100A (en) Methods of using and compositions comprising n-desmethylzolpidem

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase